鹭燕医药(002788) - 2025 Q3 - 季度财报

Financial Performance - The company's revenue for Q3 2025 reached ¥5,455,376,481.11, representing a year-on-year increase of 6.81%[5] - Net profit attributable to shareholders decreased by 2.74% to ¥65,136,647.75 for the quarter, and year-to-date net profit fell by 14.64% to ¥219,666,531.25[5] - The basic earnings per share remained stable at ¥0.17, while the diluted earnings per share were not applicable[5] - Total operating revenue for the current period reached ¥15,855,458,775.65, an increase from ¥15,413,532,406.63 in the previous period, representing a growth of approximately 2.87%[22] - Net profit for the current period was ¥218,463,133.91, down from ¥257,901,103.73 in the previous period, reflecting a decrease of approximately 15.30%[24] - Basic earnings per share decreased to ¥0.57 from ¥0.66, indicating a decline of about 13.64%[24] - The total comprehensive income for the current period was ¥218,260,721.96, down from ¥257,833,211.58 in the previous period, a decrease of approximately 15.34%[24] Assets and Liabilities - Total assets increased by 3.19% to ¥13,042,285,874.25 compared to the end of the previous year[5] - The total assets of Luyan Pharmaceutical Co., Ltd. as of September 30, 2025, amounted to 13.0423 billion yuan, an increase from 12.6386 billion yuan in the previous period[20] - The total liabilities of the company rose to 9.7785 billion yuan, compared to 9.4467 billion yuan previously, indicating an increase of approximately 3.5%[20] - The company's cash and cash equivalents decreased from 576.8 million yuan to 459.2 million yuan, representing a decline of approximately 20.4%[18] - Short-term borrowings increased from 3.8747 billion yuan to 4.0373 billion yuan, reflecting a rise of about 4.2%[20] - The company's inventory decreased from 2.8648 billion yuan to 2.7494 billion yuan, a reduction of about 4%[18] - The company's long-term borrowings decreased significantly from 648.4 million yuan to 344.4 million yuan, a decline of approximately 46.8%[20] Cash Flow - Cash flow from operating activities for the year-to-date period was ¥329,702,878.75, reflecting a 10.74% increase[5] - Cash flow from operating activities generated a net cash inflow of ¥329,702,878.75, compared to ¥297,724,410.97 in the previous period, an increase of approximately 10.74%[25] - Cash flow from investing activities resulted in a net outflow of ¥193,497,945.16, improving from a net outflow of ¥301,756,472.35 in the previous period[26] - Cash flow from financing activities showed a net outflow of ¥242,673,248.35, worsening from a net outflow of ¥121,749,663.93 in the previous period[27] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 22,747, with the largest shareholder holding 35.53% of the shares[11] - The company reported a total equity attributable to shareholders of ¥3,240,052,429.22, an increase of 2.46% from the previous year-end[5] - The total equity attributable to the parent company increased from 3.1622 billion yuan to 3.2401 billion yuan, showing a growth of approximately 2.5%[20] Legal Matters - The company has initiated legal proceedings against Guizhou Mingrun Construction Engineering Co., Ltd. for compensation of 39.6973 million yuan, with a court ruling awarding 31.6283 million yuan[15] - The company plans to continue pushing for the fulfillment of obligations related to the execution cases involving multiple guarantors[15] Impairment and Gains - The company reported a significant reduction in credit impairment losses, decreasing by 46.82% to -¥9,317,325.88 compared to the same period last year[9] - Non-recurring gains and losses for the quarter totaled -¥1,532,244.96, indicating a negative impact on overall profitability[6] - The company reported a tax expense of ¥69,793,093.78, compared to ¥75,903,320.59 in the previous period, indicating a reduction of about 8.30%[24]